A detailed history of Envestnet Asset Management Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 44,976 shares of TGTX stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,976
Previous 37,879 18.74%
Holding current value
$1.33 Million
Previous $673,000 56.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$17.21 - $25.28 $122,139 - $179,412
7,097 Added 18.74%
44,976 $1.05 Million
Q2 2024

Aug 08, 2024

SELL
$13.32 - $19.19 $13,346 - $19,228
-1,002 Reduced 2.58%
37,879 $673,000
Q1 2024

May 13, 2024

SELL
$13.02 - $21.3 $101,894 - $166,693
-7,826 Reduced 16.76%
38,881 $591,000
Q4 2023

Feb 13, 2024

BUY
$6.68 - $18.81 $35,798 - $100,802
5,359 Added 12.96%
46,707 $797,000
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $113,077 - $358,439
13,526 Added 48.62%
41,348 $345,000
Q2 2023

Aug 04, 2023

BUY
$15.48 - $35.0 $185,342 - $419,055
11,973 Added 75.54%
27,822 $691,000
Q1 2023

May 11, 2023

BUY
$10.23 - $19.34 $55,180 - $104,319
5,394 Added 51.59%
15,849 $238,000
Q4 2022

Feb 07, 2023

BUY
$5.01 - $11.83 $52,379 - $123,682
10,455 New
10,455 $123,000
Q4 2021

Feb 04, 2022

SELL
$15.2 - $35.51 $130,324 - $304,462
-8,574 Closed
0 $0
Q3 2021

Oct 07, 2021

SELL
$21.78 - $40.45 $83,787 - $155,611
-3,847 Reduced 30.97%
8,574 $285,000
Q2 2021

Aug 04, 2021

BUY
$32.5 - $48.96 $49,172 - $74,076
1,513 Added 13.87%
12,421 $482,000
Q1 2021

May 04, 2021

BUY
$41.61 - $54.3 $172,847 - $225,562
4,154 Added 61.5%
10,908 $526,000
Q4 2020

Feb 02, 2021

BUY
$25.27 - $54.9 $170,673 - $370,794
6,754 New
6,754 $351,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.